<img src="https://pubads.g.doubleclick.net/activity;dc_iu=/5206/invc.invc/VisibleAlpha_Blog_RT;ord=1?" width="1" height="1" border="0/">

The Edge | Company Analysis - Health Care

Company Analysis Company Analysis - Health Care
Jun 08. 2020

Moderna’s COVID-19 Vaccine Estimates Highlight Analyst Disharmony

Moderna’s novel coronavirus vaccine (mRNA-1273) is a front-running candidate to be one of the first available to market. If successful, the ...

author: Johnathan Ritucci

Company Analysis Company Analysis - Health Care
May 06. 2020

Gilead Analysts Begin Forecasting Remdesivir Sales for Covid-19 Treatment

The U.S. Food and Drug Administration (FDA) recently approved Gilead’s antiviral Remdesivir for emergency use authorization (EUA) as a treatment ...

author: Johnathan Ritucci